Filing Flows › AbbVie (ABBV) › Takeover & LBO
Is AbbVie (ABBV) a takeover target?
A leveraged buyout at today's price plus 30% ($378.14 a share) would return about 3% a year to a private-equity buyer over 5 years; the most a buyer could pay for a 20% return is $210.36 a share (−28% against today's $290.88). At $723.8B it would be larger than any buyout on record (the model flags anything over $60 billion), so this is a thought experiment more than a prospect. Historically 2.9% of companies with its figures were bought within a year (0.59× the average).
The buyout, step by step
| Entry | Amount | How |
|---|---|---|
| Offer price a share | $378.14 | today's $290.88 plus 30% |
| × shares | 1,772.0 million | |
| = Equity value | $670.1B | |
| + Debt refinanced | $64.5B | |
| − Cash | $10.8B | |
| + Other claims | $45.0M | preferred stock, minority interests |
| = Enterprise value | $723.8B | 25.0× EBITDA of $28.9B |
| Fees | $14.5B | 2% of the price |
| New debt | $159.2B | 5.5× EBITDA at 7.65% a year; the limit that binds: 5.5× EBITDA |
| Buyer's own money | $579.1B | 78% of the cost |
5 years under the buyer
| Year | Revenue | EBITDA | Interest | Free cash flow | Debt left |
|---|---|---|---|---|---|
| Year 1 | $71.3B | $31.3B | $12.2B | $15.2B | $144.0B |
| Year 2 | $76.1B | $33.4B | $11.0B | $17.9B | $126.1B |
| Year 3 | $80.3B | $35.2B | $9.6B | $20.5B | $105.6B |
| Year 4 | $83.7B | $36.7B | $8.1B | $23.1B | $82.5B |
| Year 5 | $86.2B | $37.8B | $6.3B | $25.5B | $57.0B |
The exit and the buyer's return
| Exit | Amount | |
|---|---|---|
| Exit multiple | 19.7× EBITDA | today's trading multiple, before any premium |
| Enterprise value at exit | $743.4B | |
| − Debt left | $57.0B | |
| = Buyer's equity | $686.4B | |
| Money multiple | 1.19× | on $579.1B put in |
| Buyer's yearly return (IRR) | 3.5% |
Price against return
What the buyer makes at other premiums over today's $290.88; the IRR reaches 20% at $210.36 a share.
| Premium | Price a share | Buyer's IRR |
|---|---|---|
| 10% | $319.97 | 7.7% |
| 20% | $349.06 | 5.4% |
| 30% | $378.14 | 3.5% |
| 40% | $407.23 | 1.7% |
| 50% | $436.32 | 0.1% |
The figures used
| Figure | Amount | |
|---|---|---|
| Revenue, last 12 months | $66.0B | |
| EBITDA, last 12 months | $28.9B | 43.8% of revenue |
| Depreciation and amortization | $7.7B | |
| Capital spending | $1.2B | |
| Debt | $64.5B | |
| Cash | $10.8B | |
| Share price | $290.88 | on Nov 5, 2026 |
Fixed rules, the same as the interactive view's starting point: the shares are bought at today's price plus 30%, the company's debt is refinanced and fees take 2%. New debt is the least of 5.5× EBITDA, 65% of the price and the amount whose interest EBITDA covers 2 times, at 7.65% a year (SOFR 3.89% plus the high-yield B spread 3.26% plus 0.5%, rates of Oct 15, 2026). Revenue grows 8.0% in the first year — the company's own rate, held between −3% and +8% — fading to 3% by year 5; the EBITDA margin, depreciation and capital spending stay at today's share of revenue; working capital takes 10% of each year's added revenue; tax is 19% of profit after interest. Every dollar of free cash flow repays debt. After 5 years the buyer sells at today's multiple of EBITDA.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, AbbVie would cost about $392.69 a share, $695.8B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $354.87 | $628.8B |
| Median | 35% | $392.69 | $695.8B |
| High end (a quarter paid more) | 45% | $421.78 | $747.4B |
The odds, from history
Historically 2.9% of companies with its figures were bought within a year (0.59× the average). Its figures put it in decile 2 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
AbbVie's latest quarter
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
Questions
Is AbbVie being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy AbbVie?
A leveraged buyout at today's price plus 30% ($378.14 a share) would return about 3% a year to a private-equity buyer over 5 years; the most a buyer could pay for a 20% return is $210.36 a share (−28% against today's $290.88). At $723.8B it would be larger than any buyout on record (the model flags anything over $60 billion), so this is a thought experiment more than a prospect.
What would a takeover of AbbVie cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, AbbVie would cost about $392.69 a share, $695.8B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.